Shaping healthcare policy for better care
We connect you to lawmakers and agencies, driving decisions that advance your mission.
A powerful advocate for your most critical challenges
Together, we build constructive relationships with lawmakers to champion the issues that impact your organization, and patients, the most.
2026 advocacy
- May 18 - Vizient expresses support for increasing funding for Children's Graduate Medical Education in FY 2027 to $1.2 billion
- May 11 - Vizient endorses the Drug Origin Transparency Act of 2026
- April 6 – Vizient comments to Office of the National Coordinator for Health Information Technology Policy (ONC) on United States Core Data for Interoperability Draft Version 7
- March 30 – Vizient comments to CMS on the Advance Notice of Proposed Rulemaking on Strengthening the Domestic Supply Chain for PPE and Essential Medicines
- March 13 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027 proposed rule
- February 23 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the Global Benchmark for Efficient Drug Pricing (GLOBE) Model proposed rule
- January 26 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program
- January 6 - Vizient comments to the Partnership for Quality Management (P4QM) on the 2025 Measures Under Consideration (MUC) List
- January 6 - Vizient comments to the Food and Drug Administration (FDA) on draft guidance for industry, “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies”
Previous advocacy
See our history of advocating for your needs.
- October 7 – Vizient responds to the Department of Commerce’s request for comments (RFC) on the national security effects of imports of personal protective equipment (PPE), medical consumables, and medical equipment, including devices
- September 23 – Vizient responds to the Food and Drug Administration (FDA) and United States Department of Agriculture’s (USDA) Ultra-Processed Foods Request for Information (RFI)
- September 12 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the CY 2026 Outpatient Prospective Payment System (OPPS) proposed rule
- September 12 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the CY 2025 Physician Fee Schedule (PFS) Proposed Rule
- September 9 - Vizient offers support for the Resident Physician Shortage Reduction Act of 2025
- September 8 – Vizient comments to the Health Resources & Services Administration (HRSA) Office of Pharmacy Affairs (OPA) on the 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program
- September 5 - Vizient letter to congressional leadership urging action to avoid Medicaid disproportionate share hospital (DSH) program reductions
- August 12 – Vizient endorses the Protecting Health Care and Lowering Costs Act
- August 6 - Vizient endorses the Protect Medicaid and Rural Hospitals Act
- July 29 – Vizient endorses the Resident Physician Shortage Reduction Act of 2025
- July 29 – Vizient endorses the Biosimilar Red Tape Elimination Act
- July 15 – Vizient endorses the Mapping America's Pharmaceutical Supply (MAPS) Act
- July 14 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on Implementation of Prior Authorization for Select Services under the Wasteful and Inappropriate Services Reduction (WISeR) Model
- July 14 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the Preserving Medicaid Funding for Vulnerable Populations — Closing a Health Care-Related Tax Loophole proposed rule
- July 2 – Vizient responds to the Centers for Medicare and Medicaid Services (CMS) Hospital Price Transparency Accuracy and Completeness Request for Information (RFI)
- June 27 – Vizient submits comments to the Agency for Healthcare Research and Quality (AHRQ) on Opportunities to Update the Patient Safety Indicators (PSIs)
- June 26 - Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the Medicare Drug Price Negotiation Program (MDPNP) Draft Guidance
- June 10 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the fiscal year (FY) 2026 Hospital Inpatient Prospective Payment System (IPPS) proposed rule
- May 30 - Vizient expresses support for increasing funding for Children's Graduate Medical Education in FY 2026 to $778 million
- May 27 - Vizient endorses the Save Healthcare Workers Act
- May 8 - Vizient endorses legislation to lower prescription drugs costs and increase access to generics and biosimilars
- May 7 – Vizient comments to the Department of Commerce regarding the imports of pharmaceuticals and pharmaceutical ingredients and their derivative products
- April 14 - Vizient comments to the Assistant Secretary for Technology Policy (ASTP) on the United States Core Data for Interoperability (USCDI) Draft Version 6
- March 18 – Vizient comments to the Drug Enforcement Administration (DEA) on the Special Registrations for Telemedicine and Limited State Telemedicine Regulations proposed rule
- March 7 – Vizient comments to the HHS Office of Civil Rights on the proposed Health Insurance Portability and Accountability Act (HIPAA) Security Rule to Strengthen the Cybersecurity of Electronic Protected Health Information (ePHI)
- March 4 - Vizient letter to the President and Secretary of Homeland Security regarding recently enacted tariffs on products imported from Canada, Mexico and China
- February 24 - Vizient letter to congressional leadership urging permanent or long-term access to telehealth services
- February 4 - Vizient letter to the President and Secretary of Homeland Security regarding recently announced tariffs on products imported from Canada, Mexico and China
- January 27 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program proposed rule
- December 20 – Vizient comments on the Centers for Medicare & Medicaid Services (CMS) Information Collection Request (ICR) on implementation of the Medicare Drug Price Negotiation Program (MDPNP)
- December 20 – Vizient comments to the Partnership for Quality Management (P4QM) on the 2024 Measures Under Consideration (MUC) list
- October 24 – Vizient submits policy priority requests to congressional leadership for the remainder of the 118th Congress
- October 14 - Vizient comments to EPA regarding Recommendations of Specifications, Standards and Ecolabels for Federal Purchasing
- September 10 – Vizient joins over 300 industry stakeholders in letters to Congress and the White House urging a two-year extension of DEA telemedicine flexibilities
- September 9 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the CY 2025 Physician Fee Schedule (PFS) Proposed Rule
- September 9 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the CY 2025 Outpatient Prospective Payment System (OPPS) proposed rule
- August 20 – Vizient comments to the Food and Drug Administration (FDA) on draft guidance “Considerations for Demonstrating Interchangeability with a Reference Product: Update”
- August 16 – Vizient endorses the Health Workforce Innovation Act
- August 2 – Vizient responds to bipartisan House request for information (RFI) on Next-Generation Cures legislation
- July 2 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027
- June 28 - Vizient Urges U.S. Trade Representative Not to Finalize Tariffs on Imports of Medical Devices and Supplies from China – Cautioning of Potential Supply Disruptions
- June 24 – Vizient endorsed coalition letter responding to the Senate Finance Committee Bipartisan Medicare Graduate Medical Education (GME) Working Group’s Draft Proposal Outline and Questions for Consideration
- June 10 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the fiscal year (FY) 2025 Hospital Inpatient Prospective Payment System (IPPS) for Acute Care Hospitals and Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals proposed rule
- May 29 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the Request for Information (RFI) on Medicare Advantage (MA) Data
- May 16 - Vizient endorsed coalition letter calling for $758 million in FY 2025 funding for Children’s Hospital Graduate Medical Education (CHGME)
- April 15 - Vizient comments to the Office of the National Coordinator (ONC) on United States Core Data for Interoperability (USCDI) Draft Version 5
- April 11 - Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the “Medicare Program; Strengthening Oversight of Accrediting Organizations (AOs) and Preventing AO Conflict of Interest, and Related Provisions” proposed rule
- April 1 – Vizient responds to the discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act) and supplemental request for information (RFI)
- March 14 - Vizient endorses the Mapping America’s Pharmaceutical Supply (MAPS) Act
- February 22 – Vizient endorses the Assistance for Rural Community Hospitals (ARCH) Act
- February 16 – Vizient endorses legislation to address patent thickets
- February 13 – Vizient endorses the Affordable Prescriptions for Patients Act
- January 24 – Vizient endorsed coalition letter in support of the Safety from Violence for Healthcare Employees (SAVE) Act
- January 5 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) regarding Contract Year 2025 policy and technical changes to the Medicare Advantage (MA or Part C) and Medicare Prescription Drug Benefit (Part D) programs
- January 2 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC) on the “21st Century Cures Act: Establishment of Disincentives for Health Care Providers That Have Committed Information Blocking” proposed rule
- December 22 - Vizient comments to the Partnership for Quality Management (P4QM) on the 2023 Measures Under Consideration (MUC) list
- December 14 – Vizient comments on the Food and Drug Administration’s (FDA’s) Request for Comments on the Quality Management Maturity (QMM) Program for Drug Manufacturing Establishments
- December 4 - Vizient comments on the Drug Enforcement Administration’s (DEA's) Notice “Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2024"
- November 29 - Vizient endorsed coalition letter on proposed Medicaid managed care rule includes provisions related to state directed payments (SDPs)
- October 17 – Vizient comments to the Departments of Treasury, Labor, and Health and Human Services on the Requirements Related to the Mental Health Parity and Addiction Equity Act proposed rule
- October 3 – Vizient responds to the House Ways and Means Committee’s Request for Information (RFI) on Improving Access to Health Care in Rural and Underserved Areas
- September 20 – Vizient endorses the Safety from Violence for Healthcare Employees (SAVE) Act
- September 11 – Vizient comments to the Food and Drug Administration (FDA) on Implementation Challenges Associated with the Drug Supply Chain Security Act (DSCSA)
- September 11 – Vizient comments to the Centers for Medicare & Medicaid Services (CMS) on the calendar year (CY) 2024 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) proposed rule
- September 11 – Vizient comments to the Centers for Medicare & Medicaid Services (CMS) on the calendar year (CY) 2024 Medicare Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed rule
- September 1 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-2022
- August 17 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the Request for Information (RFI) regarding the design of a future episode-based payment model
- July 21 – Vizient endorses the Biosimilar Red Tape Elimination Act
- July 3 – Vizient endorses the Drug Origin Transparency Act
- June 27 – Vizient comments to the Environmental Protection Agency (EPA) on the proposed rule on “National Emission Standards for Hazardous Air Pollutants: Ethylene Oxide Emissions Standards for Sterilization Facilities Residual Risk and Technology Review”
- June 27 – Vizient comments to the Environmental Protection Agency (EPA) on the proposed interim decisions for ethylene oxide (EtO) and the draft risk assessment addendum
- June 20 – Vizient comments to the Food and Drug Administration (FDA) on the Global Unique Device Identification (GUDID)_ACCESS Database
- June 20 – Vizient comments to the Office of the National Coordinator (ONC) on the proposed rule regarding the Health Data, Technology, and Interoperability
- June 14 – Vizient endorses the Preserving Patient Access to Home Infusion Act
- June 12 – Policy Solutions to Address Prescription Drug Shortages
- June 7 – Vizient endorses the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023
- June 9 – Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on the FY 2024 Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) Prospective Payment System proposed rule
- May 30 – Vizient endorses the Biologics Competition Act of 2023
- May 23 – Vizient endorsed coalition letter in opposition to Section 302 of H.R. 3561 and additional site-neutral payment policies
- May 17 – Vizient endorses the Rural Hospital Closure Relief Act of 2023
- May 17 – Vizient endorses the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2023
- May 8 – Vizient endorses the Resident Physician Shortage Reduction Act
- May 1 – Vizient comments to CMS on the Medicare Disproportionate Share Hospital Payments: Counting Certain Days Associated with Section 1115 Demonstrations in the Medicaid Fraction proposed rule
- April 21 - Vizient comments to Centers for Medicare & Medicaid Services (CMS) on the Medicaid Program Disproportionate Share Hospital Third-Party Payer Rule
- April 21 - Vizient endorses the Supporting Safety Net Hospitals Act
- April 19 - Vizient endorses the Safety from Violence for Healthcare Employees (SAVE) Act.
- April 17 - Vizient comments to the Office of the National Coordinator (ONC) on the United States Core Data for Interoperability (USCDI) Draft Version 4
- April 14 - Vizient comments to the Centers for Medicare and Medicaid Services (CMS) on Medicare Drug Price Negotiation Program Guidance
- April 12 - Vizient comments to the Office of Management and Budget (OMB) on Initial Proposals for Updating Race and Ethnicity Statistical Standards
- April 11 - Vizient endorses the Preserving Rules Ordered for the Entities Covered Through (PROTECT) 340B Act
- April 11 - Vizient endorses the Save Rural Hospitals Act
- March 31 – Vizient endorses the Resident Physician Shortage Reduction Act of 2023
- March 31 – Vizient comments on the Drug Enforcement Administration (DEA) Proposed Rule on telemedicine prescribing of controlled substances
- March 31 – Vizient comments on the Drug Enforcement Administration (DEA) Proposed Rule to expand access to buprenorphine via telemedicine encounters
- March 31 – Vizient comments on the Centers for Medicare and Medicaid Services (CMS) Medicare Part B Inflation Rebate Program Guidance1 and Medicare Part D Inflation Rebate Program Initial Guidance
- March 29 – Vizient responds to the Senate Health, Education, Labor & Pensions (HELP) Committee’s Request for Information (RFI) on upcoming PAHPA reauthorization
- March 21 - Vizient endorsed coalition letter calling for $738 million in FY 2024 funding for Children’s Hospital Graduate Medical Education (CHGME)
- March 20 - Vizient comments to the to the Department of Labor (DoL) Employment and Training Administration (ETA) on the request for information (RFI) on sector strategies to meet critical workforce needs across industries, including healthcare.
- March 20 - Vizient comments to the Senate Health, Education, Labor & Pensions (HELP) Committee on the request for information (RFI) regarding healthcare workforce challenges
- March 13 - Vizient shares feedback with House members on the reauthorization of the Pandemics and All-Hazards Preparedness Act (PAHPA)
- March 13 - Vizient comments to CMS on prior authorization proposed rule
- March 6 - Vizient urges Congress to address the Medicaid disproportionate share hospital (DSH) cuts scheduled to begin in fiscal year (FY) 2024
- February 13 - Vizient comments to CMS on the Contract Year 2024 Medicare Advantage and Part D Proposed Rule
- February 2 - Vizient submits comments to FDA regarding Drug Supply Chain Security Act (DSCSA) Implementation and Readiness Efforts for 2023
- January 31 - Vizient submits comments to HHS regard Confidentiality of Substance Use Disorder Patient Records
- January 30 - Vizient submits comments to HRSA regarding proposed revisions to the current 340B administrative dispute resolution final rule
- January 26 - Vizient comments to the Agency for Healthcare Research and Quality (AHRQ) on the request for information (RFI) on Creating a National Healthcare System Action Alliance To Advance Patient Safety
- January 12 - Vizient comments to the National Quality Forum (NQF) on the Measure Application Partnership’s (MAP) draft recommendations for CMS
- January 9 - Vizient letter to CMS on 340B Remedy for Repayment of Unlawful Cuts to Part B 340B-Purchased Drugs
Reach out
If you have questions about specific legislative or regulatory developments, please contact the Vizient Public Policy and Government Relations team at (202) 354-2600.
Our Vizient DC office address is:
799 9th Street NW, Suite 210
Washington, D.C. 20001
Take action
Ready to amplify your voice?
Connect with our experts to drive regulatory changes that multiply your performance.